EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction

Senthil Selvaraj, Shachi Patel, Andrew J Sauer, Robert W McGarrah, Philip Jones, Lydia Coulter Kwee, Sheryl L Windsor, Olga Ilkayeva, Michael J Muehlbauer, Christopher B Newgard, Barry A Borlaug, Dalane W Kitzman und 4 weitere

JACC: Heart Failure · 2024-06 · 12 (6) · 999-1011

DOI: 10.1016/j.jchf.2024.02.018 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Heart Failure, 2024-06. Verfasst von Senthil Selvaraj und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA; Duke Molecular Physiology Institute, Dur…. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Heart Failure, Stroke Volume. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIA NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although sodium glucose co-transporter 2 inhibitors (SGLT2is) improve heart failure (HF)-related symptoms and outcomes in HF with preserved ejection fraction (HFpEF), underlying mechanisms remain unclear. In HF with reduced EF, dapagliflozin altered ketone and fatty acid metabolites vs placebo; however, metabolite signatures of SGLT2is have not been well elucidated in HFpEF. OBJECTIVES: The goal of this study was to assess whether SGLT2i treatment altered systemic metabolic pathways and their relationship to outcomes in HFpEF. METHODS: Targeted profiling of 64 metabolites was performed from 293 participants in PRESERVED-HF (Dapagliflozin in PRESERVED Ejection Fraction Heart Failure), a 12-week, placebo-controlled trial of dapagliflozin. Linear regression assessed changes in metabolite factors defined by principal components analysis (PCA) with dapagliflozin vs placebo. The relationship between changes in metabolite factors with changes in study endpoints was also assessed. RESULTS: The mean age was 70 ± 11 years, 58% were female, and 29% were Black. There were no significant differences in 12 PCA-derived metabolite factors between treatment arms, including metabolites reflecting ketone, fatty acid, or branched-chain amino acid (BCAA) pathways. Combining treatment arms, changes in BCAAs and branched-chain ketoacids were negatively associated with changes in N-terminal pro-B-type natriuretic peptide; changes in medium-/long-chain acylcarnitines were positively associated with changes in N-terminal pro-B-type natriuretic peptide and negatively associated with changes in 6-minute walk test distance; and changes in ketones were negatively associated with changes in weight, without treatment interaction. CONCLUSIONS: Leveraging targeted metabolomics in a placebo-controlled SGLT2i trial of HFpEF, dapagliflozin did not alter systemic metabolic as reflected by circulating metabolites, in contrast with reported effects in HF with reduced ejection fraction. Metabolite biomarkers reflecting BCAA, ketone, and fatty acid metabolism were associated with markers of disease severity, suggesting a role for potential novel treatment targets. (Dapagliflozin in PRESERVED Ejection Fraction Heart Failure [PRESERVED-HF]; NCT03030235).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesHeart FailureStroke VolumeSodium-Glucose Transporter 2 InhibitorsMetabolomicsHumansFemaleAgedMaleMiddle AgedFatty AcidsNatriuretic Peptide, BrainBiomarkersPeptide Fragments

Stichwörter der Autor:innen

SGLT2iacylcarnitinebranched-chain amino acidsheart failure with preserved ejection fractionketone bodiesmetabolomics

Substanzen

Benzhydryl CompoundsdapagliflozinGlucosidesSodium-Glucose Transporter 2 InhibitorsFatty AcidsNatriuretic Peptide, Brainpro-brain natriuretic peptide (1-76)BiomarkersPeptide Fragments

Autor:innen und Institutionen

  • Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA; Duke Molecular Physiology Institute, Durham, North Carolina, USA.
  • Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.
  • Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA; University of Missouri-Kansas City, Kansas City, Missouri, USA.
  • Duke Molecular Physiology Institute, Durham, North Carolina, USA.
  • Duke Molecular Physiology Institute, Durham, North Carolina, USA; Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Förderung

  • NHLBI NIH HHS
  • NIA NIH HHS
  • NIDDK NIH HHS
  • AstraZeneca Pharmaceuticals LP

Zitieren

APA

Selvaraj, S., Patel, S., Sauer, A. J., McGarrah, R. W., Jones, P., Kwee, L. C., Windsor, S. L., Ilkayeva, O., Muehlbauer, M. J., Newgard, C. B., Borlaug, B. A., Kitzman, D. W., Shah, S. J., Shah, S. H., Kosiborod, M. N., & PRESERVED-HF Investigators (2024). Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 12(6), 999-1011. https://doi.org/10.1016/j.jchf.2024.02.018

Vancouver

Selvaraj S, Patel S, Sauer AJ, McGarrah RW, Jones P, Kwee LC, et al. Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure. 2024;12(6):999-1011. doi:10.1016/j.jchf.2024.02.018

BibTeX
@article{Selvaraj2024,
  author = {Selvaraj, Senthil and Patel, Shachi and Sauer, Andrew J and McGarrah, Robert W and Jones, Philip and Kwee, Lydia Coulter and Windsor, Sheryl L and Ilkayeva, Olga and Muehlbauer, Michael J and Newgard, Christopher B and Borlaug, Barry A and Kitzman, Dalane W and Shah, Sanjiv J and Shah, Svati H and Kosiborod, Mikhail N and PRESERVED-HF Investigators, PRESERVED-HF Investigators},
  title = {Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction},
  journal = {JACC: Heart Failure},
  year = {2024},
  volume = {12},
  number = {6},
  pages = {999--1011},
  doi = {10.1016/j.jchf.2024.02.018}
}
Kostenlos starten →